A possible new class of small molecule drugs that simultaneously block two coveted goals in the treatment of pain has been discovered by a team of researchers from the Duke University.
Duke University Scientists discover a new class of analgesics
These experiments proof of concept, published June 1 in Scientific Reports could lead to the development of a new drug for the treatment of conditions such as skin irritation and itching, headaches, pain in the jaw and abdominal pain resulting from the pancreas and colon. More than 100 million people suffer from chronic pain in the United States, according to a report by the Institute of Medicine, and new drugs are badly needed.
“More than 100 million people suffer from chronic pain in the United States, says a report by the Institute of Medicine, and new drugs are badly needed. “
“We are very pleased with what a first chapter of a very promising story,” said Wolfgang Liedtke, MD, Ph.D., professor of neurology, anesthesiology and neurobiology at the School of Medicine at Duke University, who treats patients with head and facial pain and other sensory disorders. “We hope to be able to develop these compounds for clinical use in humans or animals.”
In the new study, researchers initially directed to develop blockers more effective TRPV4, a molecule of his previous research has shown that transmits skin irritation caused by sunburn, and painful sensations from the head and expensive. Liedtke Duke and his collaborator Farshid Guilak blocker used a prototype TRPV4 in a study in 2009 and then set out to develop more powerful versions.
Compared with the prototype, a new drug candidates, called “16-8,” I worked 10 times more efficiently in cells with active TRPV4 that are key to the development of osteoarthritis. Also it worked well in other cell types involved in nerve cell injury, stroke and epilepsy. But to his surprise, to assess the specificity of 16-8, scientists discovered that also blocked TRPA1, which is a promising target in pain and itching research.
“As a doctor, I soon realized the enormous potential that these compounds could have, given how beneficial molecules may be double target in clinical medicine,” Liedtke said. TRPV4 and both are members TRPA1 ion channel family TRP, operating in the sensory nerve cells to directly detect painful stimuli. Other research groups are now pointing to these channels in clinical trials for pain relief.
In this study, the drug also suppressed pain 16/8 live animals, including abdominal pain in mice with inflammation in the pancreas. Called pancreatitis is extremely painful and difficult to treat, and new cases are increasing worldwide, said study co-author Rodger Liddle, MD, School of Medicine, Duke University and member of the Duke Institute of Science Brain.
Liedtke sees potential for the drug 16/08 to treat osteoarthritis and other joint pain, as well as head, face and jaw pain. In general, it could also treat pain radiating from the internal or injuries resulting bodies of nerve cells.
preclinical work group will focus on understanding the potential of the compound in these conditions use and learn more about how it works. They also hope to explore topical applications in the mucous membranes, which are present throughout the body and skin.
This article was originally published on medindia.net
Posted in: health news